Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

The refractory rheumatoid arthritis is a heterogeneous subgroup of RA patients, whosedisease has not been satisfactorily controlled with several lines of DMARDs using thetreat‐to‐target strategy. In 2024, telitacicept was approved for the treatment ofrheumatoid arthritis in China, and several case reports have demonstrated its efficacy inrefractory RA.This study plans to enroll 420 adult patients with difficult‐to‐treat rheumatoidarthritis, randomized in a 1:1 ratio to receive either telitacicept (160mg qw) plusstandard therapy or standard therapy alone for 24 weeks.